159 assets in Cervical Cancer

Therapeutic assets addressing Cervical Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fulvestrant Cervical Cancer	Terremoto Biosciences Inc.	P1/2	CC (46)
Pyruvate Cervical Cancer	Chang Gung Memorial Hospital	P2	CC (45)
Afuresertib Cervical Cancer	Laekna Limited	P1/2	CC (44)
Bemarituzumab Cervical Cancer	Centre Leon Berard	P1/2	CC (44)
Atv-1601 Cervical Cancer	Atavistik Bio, Inc	P1	CC (43)
cd70-targeting car-t cells Cervical Cancer	Chongqing Precision Biotech Co., Ltd	P1	CC (43)
cht101 Cervical Cancer	Zhejiang University	P1	CC (43)
Elimusertib Cervical Cancer	National Cancer Institute (NCI)	P1	CC (43)
Hafnium Oxide Cervical Cancer	Nanobiotix	P1	CC (43)
Idov-Immune Cervical Cancer	ViroMissile, Inc.	P1	CC (43)
Onm-501 Cervical Cancer	OncoNano Medicine, Inc.	P1	CC (43)
Talazoparib Cervical Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Nogapendekin Alfa Inbakicept Cervical Cancer	ImmunityBio, Inc.	P2	CC (42)
177lu-betabart Cervical Cancer	Radiopharm Theranostics, Ltd	P1/2	CC (41)
Alpha Tocopherol Cervical Cancer	University of Nebraska	P1/2	CC (41)
Amxt1501 Cervical Cancer	Aminex Therapeutics, Inc.	P1/2	CC (41)
Bms-936558-01 Cervical Cancer	Bristol-Myers Squibb	P1/2	CC (41)
Camizestrant Cervical Cancer	AstraZeneca	P1/2	CC (41)
Carbon Nanoparticle-Loaded Iron Cervical Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1/2	CC (41)
Cervical Cancer-Specific Car-T Cells Cervical Cancer	Shenzhen Geno-Immune Medical Institute	P1/2	CC (41)
coq10 Cervical Cancer	University of Nebraska	P1/2	CC (41)
Datopotamab Deruxtecan Cervical Cancer	AstraZeneca	P1/2	CC (41)
Dexasone Cervical Cancer	Seoul National University Hospital	P1/2	CC (41)
Eflornithine Cervical Cancer	Aminex Therapeutics, Inc.	P1/2	CC (41)
Entinostat Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Enzalutamide Cervical Cancer	Cancer Research UK	P1/2	CC (41)
Epinephrine Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-3101 (89.9%) -(Ighd) -Ighj401 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg101 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 (85.3%)-Igkj201 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa Cervical Cancer	Cancer Research UK	P1/2	CC (41)
gi-101a Cervical Cancer	GI Innovation, Inc.	P1/2	CC (41)
gm103 Cervical Cancer	GeneMedicine Co., Ltd.	P1/2	CC (41)
Gotistobart Cervical Cancer	OncoC4, Inc.	P1/2	CC (41)
hb0028 Cervical Cancer	Shanghai Huaota Biopharmaceutical Co., Ltd.	P1/2	CC (41)
Human T-Lymphocyte Activation Antigen Cd80 (Activation B7-1 Antigen, Ctla-4 Counter-Receptor B7.1, Cd80) Extracellular Domain Containing Fragment (1-208 In The Current Sequence) Fused Via Peptide Linker <Sup>209</Sup>Gsggggsggggsggggs<Sup>225</Sup> To An Fc Fragment Of Human Immunoglobulin G4 (226-454) [Homo Sapiens Ighg4*01, Hinge Ins<Sup>226</Sup>>A, S<Sup>236</Sup>>P (226-238), Ch2 F<Sup>242</Sup>>A, L<Sup>243</Sup>>A, T<Sup>258</Sup>>Q (239-348), Ch3 M<Sup>436</Sup>>L (349-453), Chs K<Sup>455</Sup>>Del (454)] Fused Via Peptide/ Linker <Sup>455</Sup>Ggggs<Sup>459</Sup> To Human Interleukin-2 (Il-2, T-Cell Growth Factor (Tcgf)) (1-133, 460-592 In The Current Sequence), Variant (R<Sup>38</Sup>>A<Sup>497</Sup>, F<Sup>42</Sup>>A<Sup>501</Sup>), Dimer (234-234', 237-237')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Cervical Cancer	GI Innovation, Inc.	P1/2	CC (41)
Ibuprofen Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
ilb2109 Cervical Cancer	Innolake Biopharm	P1/2	CC (41)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Cc Chemokine Receptor Ccr8) (Human-Mus Musculus Monoclonal Bms-986340 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Bms-986340 ?-Chain, Dimer Cervical Cancer	Bristol-Myers Squibb	P1/2	CC (41)
Ipilimumab Cervical Cancer	Neonc Technologies, Inc.	P1/2	CC (41)
Lenvatinib Cervical Cancer	GI Innovation, Inc.	P1/2	CC (41)
Mdna11 Cervical Cancer	Medicenna Therapeutics, Inc.	P1/2	CC (41)
mdx2001 Cervical Cancer	ModeX Therapeutics, An OPKO Health Company	P1/2	CC (41)
Monoclonal Antibody Neo-201 Cervical Cancer	Precision Biologics, Inc	P1/2	CC (41)
mt-4561 Cervical Cancer	Tanabe Pharma America, Inc.	P1/2	CC (41)
neo212 Cervical Cancer	Neonc Technologies, Inc.	P1/2	CC (41)
ngm707 Cervical Cancer	NGM Biopharmaceuticals, Inc	P1/2	CC (41)
pds01adc Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Prgn-2009 Cervical Cancer	National Cancer Institute (NCI)	P1/2	CC (41)
Pumitamig Cervical Cancer	Bristol-Myers Squibb	P1/2	CC (41)
q702 Cervical Cancer	Qurient Co., Ltd.	P1/2	CC (41)
Regorafenib Cervical Cancer	Neonc Technologies, Inc.	P1/2	CC (41)
Saruparib Cervical Cancer	AstraZeneca	P1/2	CC (41)

Showing 51 to 100 of 159 assets

PreviousPage 2 of 4Next